{"disease":{"id":"recurrent-breast-cancer","name":"recurrent breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01275677","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3270,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01953588","title":"Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1473,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT01463891","title":"Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT05838066","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03315364","title":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":549,"lead_sponsor_name":"Daehwa Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03418961","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":491,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03786094","title":"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":432,"lead_sponsor_name":"Spexis AG","has_results":true},{"nct_id":"NCT07406542","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT00601900","title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":394,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02595905","title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00390455","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01881230","title":"Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":191,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT03199885","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02415387","title":"Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06769425","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06369285","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":false},{"nct_id":"NCT01987726","title":"Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01622868","title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03109249","title":"Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":false},{"nct_id":"NCT03291886","title":"Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT05301010","title":"Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT06329089","title":"Reoperative Sentinel Lymph Node Biopsy in Patients With Recurrent Ipsilateral Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":97,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT06799065","title":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Accent Therapeutics","has_results":false},{"nct_id":"NCT01908101","title":"Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT02311933","title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03326102","title":"Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Daehwa Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03281902","title":"Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00807859","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00684983","title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01730833","title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05621434","title":"A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT07121244","title":"A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Radionetics Oncology","has_results":false},{"nct_id":"NCT01327781","title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02015559","title":"Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT00733408","title":"Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT01349959","title":"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT02203552","title":"Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT01084057","title":"Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03530696","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT04521764","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02422498","title":"Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}